Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Détails

ID Serval
serval:BIB_D9BACB56B9AE
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Périodique
The lancet. HIV
Auteur(s)
Julg B., Dee L., Ananworanich J., Barouch D.H., Bar K., Caskey M., Colby D.J., Dawson L., Dong K.L., Dubé K., Eron J., Frater J., Gandhi R.T., Geleziunas R., Goulder P., Hanna G.J., Jefferys R., Johnston R., Kuritzkes D., Li J.Z., Likhitwonnawut U., van Lunzen J., Martinez-Picado J., Miller V., Montaner L.J., Nixon D.F., Palm D., Pantaleo G., Peay H., Persaud D., Salzwedel J., Salzwedel K., Schacker T., Sheikh V., Søgaard O.S., Spudich S., Stephenson K., Sugarman J., Taylor J., Tebas P., Tiemessen C.T., Tressler R., Weiss C.D., Zheng L., Robb M.L., Michael N.L., Mellors J.W., Deeks S.G., Walker B.D.
ISSN
2352-3018 (Electronic)
ISSN-L
2352-3018
Statut éditorial
Publié
Date de publication
04/2019
Peer-reviewed
Oui
Volume
6
Numéro
4
Pages
e259-e268
Langue
anglais
Notes
Publication types: Consensus Development Conference ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.
Mots-clé
Anti-Retroviral Agents/administration & dosage, HIV Infections/drug therapy, Humans, Sustained Virologic Response, Viral Load, Withholding Treatment/standards
Pubmed
Web of science
Création de la notice
09/04/2019 7:22
Dernière modification de la notice
26/06/2020 5:21
Données d'usage